Document Classification

Section Type: RESULTS

Text: There was no evidence of a differential effect of apixaban over warfarin in patients with and without valvular heart disease in reducing stroke and systemic embolism (hazard ratio [HR], 0. 70 ; 95 % confidence interval [CI], 0. 51-0. 97 and HR, 0. 84 ; 95 %, CI 0. 67-1. 04 ; interaction P = 0. 38), causing less major bleeding (HR, 0. 79 ; 95 % CI, 0. 61-1. 04 and HR, 0. 65 ; 95 % CI, 0. 55-0. 77 ; interaction P = 0. 23), and reducing mortality (HR, 1. 01 ; 95 % CI, 0. 84-1. 22 and HR, 0. 84 ; 95 % CI, 0. 73-0. 96 ; interaction P = 0. 10).